PGN-202

BERWYN, Pa.--(BUSINESS WIRE)-- Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended June 30, 2023, and other recent developments. “In the second quarter, we continued to make progress with our Rx product candidates,” commented Anthony P. Mack, Chairman and Chief Executive Officer of Virpax. “As well, we strengthened the organization with the appointment of a new Chief Financial Officer (CFO), who aside from his experience with public biotech companies has a broad financial background encompassing licensing, M&A and fund raising. Additionally, we added a leading expert in liposomal drug delivery and nanotechnology to support the advancement of our leading product candidate, Probudur™. I am proud of the high caliber talent that we have attracted to Virpax, joining us as we develop our pipeline of innovative drug candidates.” “We successfully won another competitive cooperative research and development agreement (CRADA). This one is for our NobrXiol™ product candidate which is being designed to identify novel agents to meet unmet medical needs in epilepsy. We now have CRADA’s for all three of our Rx product candidates, two with the National Institutes of Health (NIH) and one with the Department of Defense (DOD). These successes reinforce our non-dilutive grant funding strategy and demonstrate how Virpax has been able to develop a team to support this effort.” “In May, our grants core team participated in the virtual CB Tech Watch Seminar showcasing our Molecular Envelope Technology (MET) and our over-the-counter (OTC) AnQlar™ product candidate for viral inhibition. Participating in this event were representatives of a number of Federal agencies including Defense Advanced Research Products Agency (DARPA), Defense Threat Reduction Agency (DTRA), and the U.S. Army and Navy among others. This was an excellent opportunity for us to introduce Virpax to these groups, and we expect it to be beneficial as we continue to apply for grant funding from the DOD.” “Finally, as we enter the second half of 2023, we anticipate reporting results from additional pre-IND studies in advance of entering the clinic in 2024, initiating studies for our Probudur and NobrXiol CRADAs by year end, submitting additional grant applications and potentially monetizing our OTC product candidates,” concluded Mr. Mack. RECENT DEVELOPMENTS On August 10, 2023, Virpax announced that it filed a new provisional patent application with the United States Patent and Trademark Office (USPTO) entitled “NSAID Formulation and Method” related to its Epoladerm™ product candidate. Epoladerm is an over-the-counter diclofenac topical spray film that the Company is developing for pain associated with Osteoarthritis. On July 24, 2023, Virpax rang the Nasdaq closing bell. On July 13, 2023, Virpax announced that it had filed a new provisional patent application with the USPTO entitled “Intranasal Delivery” related to its Envelta™ product candidate. Envelta utilizes MET for the delivery of Enkephalin intranasally for severe cancer pain and non-cancer pain. The enkephalin/MET formulation is delivered using a delivery device which propels the formulation into nose such that the enkephalin is delivered to the brain. On June 21, 2023, Virpax announced that it has entered into a CRADA with the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. NIH Division of Translational Research which conducts and funds research on brain and nervous system disorders. Virpax will be partnering with the Epilepsy Therapy Screening Program (ETSP) whose mission is to identify novel agents to address unmet medical needs in epilepsy, including the identification of next generation products focused on addressing drug resistant epilepsy, disease prevention and modification. Under the CRADA, NINDS ETSP will evaluate Virpax’s NobrXiol™ product candidate that is being developed for the management of rare pediatric epilepsy. On June 20, 2023, Virpax announced the appointment of Vinay Shah as Chief Financial Officer. Mr. Shah joins Virpax from Aravive, Inc., a clinical stage biotech company, where he served for five years as the CFO. Prior to Aravive, he was with Pacira Pharmaceuticals, Inc. for nine years in financial positions of increasing responsibilities. Mr. Shah has over 30 years of financial experience, successfully establishing financial functions, participating in licensing and M&A transactions, and engaging in fund raising activities. On May 10, 2023, Virpax announced that it had been invited to present its MET, as well as its AnQlar™ product candidate for viral inhibition that utilizes MET, at the June 8, 2023, virtual CB Tech Watch Seminar. CB Tech Watch Seminar is a forum for companies to highlight their science and technology to agencies within the DOD as well as other Federal agencies and military branches. On April 27, 2023, Virpax announced that it has engaged Dr. Pardeep Gupta, a leading expert in liposomal drug delivery and nanotechnology, to support the development of Probudur, Virpax’s proprietary patented long-acting injectable liposomal bupivacaine for postoperative pain management. Dr. Gupta’s involvement is expected to include advising on chemistry, manufacturing and controls (CMC), technology transfer and buildout required for the commercialization of Probudur. On April 5, 2023, Virpax announced the successful completion of dose ranging studies for rats and dogs in its Envelta™ development program. Envelta is the Company’s non-opioid pain product candidate for acute and chronic pain that is being funded under an in-kind grant from the National Center for Advancing Translational Sciences (NCATS), part of the NIH. SECOND QUARTER 2023 FINANCIAL RESULTS General and administrative expenses were $1.9 million for the three months ended June 30, 2023, compared to $2.6 million for the same period in 2022. The decrease was primarily due to lower legal defense costs related to litigation and was partially offset by an increase in salaries and wages, severance, and fees related to market assessment efforts. Research and development expenses were $1.3 million for the three months ended June 30, 2023, compared to $3.3 million for the same period in 2022. The decrease was primarily attributable to decreases in preclinical activities for AnQlar, NobrXiol, and Epoladerm. This was slightly offset by an increase in preclinical activity related to Probudur. The operating loss for the three months ended June 30, 2023 was $3.2 million, compared to an operating loss of $5.9 million for the same period in 2022. As of June 30, 2023, cash and cash equivalents were $14.8 million, compared to $19.0 million as of December 31, 2022. About Virpax Pharmaceuticals Virpax is developing branded, non-addictive pain management product candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta™ is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop two other product candidates. PES200 is a product candidate being developed to manage post-traumatic stress disorder (PTSD) and NobrXiol™ is a product candidate being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax recently acquired global rights to NobrXiol. Virpax is also seeking approval of two nonprescription product candidates: AnQlarTM, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit virpaxpharma.com and follow us on Twitter, LinkedIn and YouTube. Forward-Looking Statement This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's planned clinical trials, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms and include statements such as the Company continuing to make progress with its Rx product candidates, the virtual CB Tech Watch Seminar being beneficial as the Company continues to apply for grant funding from the DOD, reporting results from additional pre-IND studies in advance of entering the clinic in 2024, initiating studies for Probudur and NobrXiol CRADAs, submitting additional grant applications and potentially monetizing the Company’s OTC product candidates and the benefits anticipated from the appointment of Dr. Gupta and Mr. Shah . These statements relate to future events or the Company’s financial performance and involve known and unknown risks, uncertainties, and other factors, including the Company’s ability to successfully complete research and further development, including reporting results from additional pre-IND studies in advance of entering the clinic in 2024, and commercialization of Company drug candidates in current or future indications; the Company’s ability to obtain additional grant funding, the uncertainties inherent in clinical testing; the Company’s ability to manage and successfully complete clinical trials and the research and development efforts for multiple product candidates at varying stages of development; t; the timing, cost and uncertainty of obtaining regulatory approvals for the Company’s product candidates; the Company’s ability to protect its intellectual property; the loss of any executive officers or key personnel or consultants and the ability of such executives to make valuable contributions to the Company; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s product candidates; the Company’s ability to continue to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete clinical trials that the Company plans to initiate; and other factors listed under “Risk Factors” in our annual report on Form 10-K and quarterly reports on Form 10-Q that the Company files with the U.S. Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. CONDENSED BALANCE SHEETS June 30, 2023 December 31, 2022* (Unaudited) ASSETS Current assets Cash $ 14,804,000 $ 18,995,284 Prepaid expenses and other current assets 1,147,368 678,365 Total current assets 15,951,368 19,673,649 Total assets $ 15,951,368 $ 19,673,649 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities Accounts payable and accrued expenses $ 1,646,770 $ 1,094,590 Estimated litigation liability 2,000,000 2,000,000 Total current liabilities 3,646,770 3,094,590 Total liabilities 3,646,770 3,094,590 Commitments and contingencies Stockholders' equity Preferred stock, par value $0.00001, 10,000,000 shares authorized; no shares issued and outstanding as of both June 30, 2023 and December 31, 2022 — — Common stock, $0.00001 par value; 100,000,000 shares authorized, 11,714,284 shares issued and outstanding as of June 30, 2023 and December 31, 2022 117 117 Additional paid-in capital 61,292,409 60,933,569 Accumulated deficit (48,987,928 ) (44,354,627 ) Total stockholders' equity 12,304,598 16,579,059 Total liabilities and stockholders' equity $ 15,951,368 $ 19,673,649 * Derived from audited financial statements CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 OPERATING EXPENSES General and administrative (net of insurance reimbursement of $0 and $1,250,000 during the three and six months ended June 30, 2023 - See Note 5) $ 1,948,700 $ 2,645,618 $ 2,364,151 $ 4,428,031 Research and development 1,290,787 3,258,471 2,526,401 6,599,877 Total operating expenses 3,239,487 5,904,089 4,890,552 11,027,908 Loss from operations (3,239,487 ) (5,904,089 ) (4,890,552 ) (11,027,908 ) OTHER INCOME Other income 126,720 19,374 257,251 6,191 Loss before tax provision (3,112,767 ) (5,884,715 ) (4,633,301 ) (11,021,717 ) Income taxes — — — — Net loss $ (3,112,767 ) $ (5,884,715 ) $ (4,633,301 ) $ (11,021,717 ) Basic and diluted net loss per share $ (0.27 ) $ (0.50 ) $ (0.40 ) $ (0.94 ) Basic and diluted weighted average common stock outstanding 11,714,284 11,712,753 11,714,284 11,710,733 CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) For the Six Months Ended June 30, 2023 2022 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ (4,633,301 ) $ (11,021,717 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 358,840 456,041 Change in operating assets and liabilities: Prepaid expenses and other current assets (469,003 ) (610,863 ) Accounts payable and accrued expenses 552,180 395,682 Net cash used in operating activities (4,191,284 ) (10,780,857 ) Net change in cash (4,191,284 ) (10,780,857 ) Cash, beginning of year 18,995,284 36,841,992 Cash, end of year $ 14,804,000 $ 26,061,135 Supplemental disclosure of cash and non-cash transactions Cash paid for interest $ — $ — Cash paid for taxes $ — $ —

▎药明康德内容团队编辑本期看点1. 同种异体CAR-T细胞疗法CB-010治疗复发/难治性B细胞非霍奇金淋巴瘤患者的疗效亮眼，患者的总缓解率（ORR）为94%，最长保持了24个月的完全缓解（CR）。2. 用于治疗活动性甲状腺眼病（TED）的在研新药VRDN-001可使慢性TED患者的症状和体征在第6周就得到快速且有临床意义的改善。3. NKGen Biotech公司公布了其用于治疗阿尔茨海默病的自然杀伤（NK）细胞疗法SNK01在1期临床试验中的积极中期数据。药明康德内容团队整理CB-010：公布1期临床试验数据 Caribou Biosciences公司公布了其同种异体CAR-T细胞疗法CB-010治疗复发/难治性B细胞非霍奇金淋巴瘤患者的长期随访数据。CB-010利用基因编辑技术生成，除了表达靶向CD19的嵌合抗原受体，还利用基因编辑技术敲除了免疫检查点蛋白PD-1的表达，旨在提高抗肿瘤活性的持久性。此次公布的结果显示，CB-010的缓解率和安全性可与已获批的自体CAR-T细胞疗法相媲美。接受单剂CB-010治疗后，患者的ORR为94%（15/16），CR率为69%（11/16），44%的患者保持CR超过6个月。截至目前，患者最长保持了24个月的CR。大B细胞淋巴瘤患者亚组中有50%的患者保持CR超过6个月，患者最长保持了18个月的CR.▲CB-010的疗效评估图（图片来源：参考资料[15]）VRDN-001：公布1/2期临床试验的新数据 VRDN-001是Viridian Therapeutics公司开发的一种用于治疗TED的抗IGF-1R单克隆抗体，可以通过亚纳摩尔级别的亲和力结合和阻断IGF-1R信号通路。这种作用机制已在TED的临床实践中得到了验证。此次公布的数据来自一项双盲、安慰剂对照的临床1/2期试验中3 mg/kg和10 mg/kg VRDN-001剂量队列的数据。结果显示，两种剂量的VRDN-001都能使慢性TED患者的眼球突出程度和临床活动评分（CAS）在第6周得到快速且有临床意义的改善，如下图所示。此外，VRDN-001在所有剂量下均显示出了良好的安全性。▲眼球突出程度结果（图片来源：参考资料[3]）▲临床活动评分结果（图片来源：参考资料[3]）SNK01：公布1期临床试验数据NKGen Biotech公司公布了其NK细胞疗法SNK01治疗阿尔茨海默病患者的1期临床试验数据。截至2023年6月30日的数据，SNK01在10名中位年龄为79岁的受试者中耐受性良好，未观察到相关严重不良事件，也未达到剂量限制性毒性。第11周（末次给药后一周）时，70%的受试者CDR-SB评分（分越高意味着患者临床功能越低）保持稳定或有改善，60%的受试者的ADAS-Cog评分（用于评估认知能力）保持稳定或有改善，50%的受试者的MMSE评分（用于评估精神状态）保持稳定或有改善。一名接受最高剂量水平治疗的受试者的MMSE评分（从14分提升至22分）、ADAS-Cog评分（从32分降低到24分）和CDR-SB评分（从10分降低到5.5分）均有显著改善。此外，观察到受试者脑脊液中的生物标志物水平保持稳定或有改善，在停止SNK01治疗3个月后，一些生物标志物出现了反弹。第22周（末次给药后3个月）时，8名可评估的受试者中，67%的受试者的CDR-SB评分保持稳定，83%的患者的ADAS-Cog评分和MMSE评分保持稳定或有改善。SP-3164：IND申请获得FDA许可SP-3164是Salarius Pharmaceuticals公司开发的分子胶类蛋白降解剂，通过诱导E3泛素连接酶和靶蛋白之间的相互作用，能够选择性地降解靶蛋白。在临床前研究中，SP-3164能够降解转录因子IKZF1和IKZF3蛋白，故而具有抗癌和免疫调节的特性。此外，SP-3164在滤泡性淋巴瘤和多发性骨髓瘤动物模型中显示出令人信服的抗肿瘤活性。近期，FDA批准了SP-3164的IND申请，允许该公司在复发/难治性非霍奇金淋巴瘤患者中进行SP-3164的1期临床试验，以评估其安全性、临床活性、药代动力学和药效学。CM24：公布1期临床试验的初步数据Purple Biotech公司公布了其靶向CEACAM1的单克隆抗体CM24联用PD-1抑制剂nivolumab治疗晚期胰腺癌患者的初步临床数据。CEACAM1是一种免疫检查点蛋白，可通过多种途径支持肿瘤免疫逃逸和存活。NET是一种网状DNA结构，覆盖着由活化的中性粒细胞释放的致癌蛋白，已被证明可包裹肿瘤并促进免疫逃避、肿瘤进展和转移。当CEACAM1与NET结合时，它将成为癌症细胞粘附的重要位点，因此被认为是预防肿瘤转移进展和免疫逃逸的潜在治疗靶点。在临床前研究中，CM24已被证明可直接与NET结合，并抑制NET诱导的癌症细胞迁移。此次研究招募了11名难治性胰腺导管腺癌患者，这些患者在接受了2线治疗后进展。该联合疗法在所有剂量水平下的耐受性均良好，无药物限制性毒性。6例患者出现3级不良反应，但均与研究药物无关。初步的疗效结果显示，接受CM24联合nivolumab治疗的患者的总生存期与三线治疗为化疗的患者的历史总生存期相当，接受化疗患者的中位总生存期为3-4个月。N-803：公布1期临床试验数据ImmunityBio公司公布了其IL-15超级拮抗剂N-803联合同种异体细胞因子诱导记忆样（CIML）NK细胞治疗晚期头颈癌患者的1期临床试验结果。N-803由与IL-15受体α/IgG1 Fc融合蛋白结合的IL-15突变体（IL-15N72D）组成。它与βγT细胞受体结合，能够直接特异性刺激CD8阳性T细胞和NK细胞，同时避免刺激调节性T细胞。与天然、非复合IL-15相比，N-803在患者体内具有更优的药代动力学特性，且能在淋巴组织中存在更长时间，表现出增强的抗肿瘤活性。该研究中，患者在接受同种异体CIML NK细胞疗法联用N-803前接受了清淋治疗加或不加CTLA-4抑制剂ipilimumab治疗。结果显示，患者产生了与持续的CIML NK细胞扩增相关的肿瘤消退。这表明，该联合疗法有望为目前预后极差的晚期头颈癌患者提供新的治疗方法。SBI-100：公布1期临床试验数据Skye Bioscience公司公布了其眼用乳剂（OE）SBI-100用于治疗青光眼和眼压增高患者的1期临床试验的最后1个健康受试者队列的数据。SBI-100 OE采用新型分子结构和纳米乳剂配方，使其中的有效成分CB1R激动剂可更好地穿透眼内组织，实现有效的局部给药，对降低眼内压具有良好的疗效。此次公布的数据显示，SBI-100 OE的耐受性良好，与先前报告的5个队列一致，没有与药物相关的严重不良事件。该公司准备在2023年第3季度将SBI-100 OE推进至针对青光眼患者的2a期临床试验。MW005：公布1/2期临床试验数据MediWound公司公布了其酶疗法MW005治疗低风险基底细胞癌的安全性和有效性数据。15名患者接受了MW005治疗并完成了研究。结果显示，MW005的安全性和耐受性良好，患者依从性高。尽管该试验的主要重点是安全性和耐受性，但值得注意的是，根据临床评估，15名患者中有11名实现了基底细胞癌的完全清除，其中，大多数患者经组织学证实实现了完全清除。Olvi-Vec：公布1期临床试验数据Genelux Corporation公司公布了其溶瘤病毒免疫疗法Olvi-Vec治疗恶性胸腔积液的恶性胸膜间皮瘤或转移性非小细胞肺癌/乳腺癌患者的1期临床试验结果。Olvi-Vec是Genelux公司专有的溶瘤病毒疫苗，经过改良以提高其安全性、肿瘤选择性和治疗潜力。此次公布的结果表明，Olvi-Vec可感染肿瘤细胞，同时降低肿瘤细胞密度，增加免疫细胞密度，证实了Olvi-Vec具有直接的细胞毒性和免疫激活作用。所有患者的中位总生存期为19.5个月，恶性胸膜间皮瘤亚组患者的中位总生存期为22个月。试验中没有出现剂量限制性毒性反应或需要减少剂量，也没有达到最大耐受剂量。因此，推荐剂量尚未确定。大家都在看▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求，欢迎点击下方图片填写具体信息。▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息参考资料（可上下滑动查看）[1] Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology. Retrieved July 15，from https://www.globenewswire.com/news-release/2023/07/10/2701623/0/en/Genelux-Corporation-Announces-Publication-of-Phase-I-Trial-Results-of-Intrapleural-Administration-of-Olvi-Vec-in-Patients-with-Malignant-Pleural-Effusion-from-Mesothelioma-Lung-or-.html[2] MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma. Retrieved July 15，from https://www.globenewswire.com/news-release/2023/07/10/2701666/30505/en/MediWound-Announces-Positive-Results-in-Its-U-S-Phase-I-II-Study-of-MW005-for-the-Treatment-of-Basal-Cell-Carcinoma.html[3] Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) . Retrieved July 15，from https://www.businesswire.com/news/home/20230710883161/en[4] First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma. Retrieved July 15，from https://www.businesswire.com/news/home/20230710291669/en[5] TANGO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TNG462 PHASE 1/2 TRIAL IN PATIENTS WITH MTAP-DELETED SOLID TUMORS. Retrieved July 15，from https://ir.tangotx.com/news-releases/news-release-details/tango-therapeutics-announces-first-patient-dosed-tng462-phase-12[6] First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours. Retrieved July 15，from https://www.businesswire.com/news/home/20230710425172/en/[7] Nacuity Pharmaceuticals Advances Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression. Retrieved July 15，from https://www.nacuity.com/media/nacuity-pharmaceuticals-advances-phase-1-2-clinical-trial-evaluating-npi-002-intravitreal-implant-for-the-delay-of-cataract-progression/[8] Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging. Retrieved July 15，from https://www.prnewswire.com/news-releases/ratio-therapeutics-in-collaboration-with-lantheus-and-pharmalogic-announce-first-patient-dosed-in-phase-i-study-evaluating-a-novel-fap-targeted-radiopharmaceutical-for-pet-imaging-301873539.html[9] HI-Bio Initiates Healthy Volunteer Study of HIB210 for Immune-Mediated Diseases. Retrieved July 15，from https://www.prnewswire.com/news-releases/hi-bio-initiates-healthy-volunteer-study-of-hib210-for-immune-mediated-diseases-301873618.html[10] IconOVir Announces New Preclinical Data Showcasing Best-in-Class Potential of ICVB-1042, its Lead Oncolytic Virus, at SITC 2022. Retrieved July 15，from https://www.businesswire.com/news/home/20230711691585/en[11] Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership. Retrieved July 15，from https://www.globenewswire.com/news-release/2023/07/13/2704421/0/en/Invectys-Announces-Initiation-of-Phase-1-2a-Clinical-Trial-in-Solid-Tumors-and-Change-in-Leadership.html#:~:text=A%20Phase%20I%2F2a%20clinical%20trial%20%28NCT05672459%29%20was%20initiated,patients%2C%20particularly%20those%20with%20kidney%20and%20ovarian%20cancers.[12] Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients. Retrieved July 15，from https://www.businesswire.com/news/home/20230710232438/en/[13] Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients. Retrieved July 15，from https://www.globenewswire.com/news-release/2023/07/11/2702641/0/en/Salarius-Pharmaceuticals-Receives-FDA-Clearance-of-SP-3164-Investigational-New-Drug-Application-to-Begin-a-Phase-1-Clinical-Trial-in-Relapsed-Refractory-Non-Hodgkin-Lymphoma-Patien.html[14] Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients. Retrieved July 15，from https://www.globenewswire.com/news-release/2023/07/11/2702616/0/en/Purple-Biotech-Reports-Positive-Results-of-CM24-Dose-Escalation-in-Advanced-Pancreatic-Cancer-Patients.html[15] Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL. Retrieved July 15，from https://www.globenewswire.com/news-release/2023/07/13/2704702/0/en/Caribou-Biosciences-Reports-Positive-Clinical-Data-from-Dose-Escalation-of-CB-010-ANTLER-Phase-1-Trial-in-r-r-B-NHL.html[16] Skye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic Emulsion. Retrieved July 15，from https://www.newsfilecorp.com/release/173386[17] NKGen Biotech Presents Interim Phase I Trial Data at 2023 Alzheimer’s Association International Conference. Retrieved July 15，from https://www.globenewswire.com/news-release/2023/07/17/2705164/0/en/NKGen-Biotech-Presents-Interim-Phase-I-Trial-Data-at-2023-Alzheimer-s-Association-International-Conference.html免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新